Modeling the effect of a combinatorial anti-CTLA antibody and radiation therapy on metastatic lung cancer.
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an inhibitory receptor that is upregulated after T-cell activation, and transmits signals that suppress T-cell activation and proliferation through the depletion of CD8+ T cells. Antibodies targeting CTLA-4 can selectively deplete regulatory T cells by antibody-mediated cellular cytotoxicity mechanisms. However, anti-CTLA-4 antibody therapy as a single treatment is limited on effectiveness to fight against immunogenic diseases like metastatic cancers. Radiation therapy (RT) on the other hand is a longstanding pillar of cancer treatment, historically utilized to treat a discrete target and provide local tumor control. Recent preclinical studies demonstrated that RT is synergistic with anti-CTLA antibody and induces systemic anti-tumor responses. In order to better understand the effect of the combination therapy on metastatic lung cancer, we developed a mathematical model using a system of impulsive differential equations. The objective of this study was to develop a predictive simulation platform to improve cancer management by manipulating dose and fractionation schedule of RT and dose and timing for the anti-CTLA-4 antibody therapy. This study is supported by NIH Grant P20GM103434 to the West Virginia IDeA Network for Biomedical Research Excellence.
How to Cite
Proceedings of the West Virginia Academy of Science applies the Creative Commons Attribution-NonCommercial (CC BY-NC) license to works we publish. By virtue of their appearance in this open access journal, articles are free to use, with proper attribution, in educational and other non-commercial settings.